CHP1

Calcineurin B homologous protein 1 · Q99653 · CHP1 on Sugi Atlas →

0 patent compounds predicted against CHP1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CHP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Tacrolimus Treatment for Refractory Autoimmune Cytopenia PHASE4UNKNOWN
SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients PHASE4RECRUITING
Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction PHASE4COMPLETED
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens PHASE3COMPLETED
Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients PHASE2UNKNOWN
Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL) PHASE2COMPLETED
Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation PHASE2COMPLETED
Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM) PHASE2COMPLETED
Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients PHASE2COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes nanRECRUITING
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer nanWITHDRAWN
Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus? nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Role of Nox2 in CNI-induced Renal Fibrosis nanCOMPLETED
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Using mTOR Inhibitors in the Prevention of BK Nephropathy nanCOMPLETED
Gene Polymorphisms in Tacrolimus Drug Interactions nanCOMPLETED
Genetics of the Early and Late Response to Allergen Challenge nanCOMPLETED
Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers nanCOMPLETED
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Biomarkers of CASH nanACTIVE_NOT_RECRUITING
Genetic Variants Associated With Adolescent Suicide Attempts nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Cytokine Gene Polymorphisms in Bone Marrow Failure nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CHP1 binder may also engage these)

ProteinNameSimilarity
Q3SYS6 1.000 Q3SYS6 →
Q5ZM44 1.000 Q5ZM44 →
Q5R7F0 1.000 Q5R7F0 →
P61023 1.000 P61023 →
P61022 1.000 P61022 →
Q810D1 0.999 Q810D1 →
Q9D869 0.989 Q9D869 →
O43745 0.988 O43745 →
P63100 0.985 P63100 →
PPP3R1 Calcineurin subunit B type 1 0.985 landscape →
P0CM55 0.985 P0CM55 →
Q5U554 0.984 Q5U554 →
P42322 0.984 P42322 →
P43081 0.984 P43081 →
Q24214 0.983 Q24214 →
P25296 0.982 P25296 →
Q63811 0.982 Q63811 →
Q2TBI5 0.982 Q2TBI5 →
Q0V9B1 0.982 Q0V9B1 →
P22728 0.982 P22728 →
P79881 0.981 P79881 →
P48451 0.980 P48451 →
P51177 0.980 P51177 →
P87072 0.980 P87072 →
G5EDN6 0.980 G5EDN6 →
P43080 0.979 P43080 →
O73761 0.979 O73761 →
Q6CGE6 0.979 Q6CGE6 →
P63099 0.978 P63099 →
B5FZ84 0.977 B5FZ84 →